Join us at ASCO 2024 – booths 19115 & 23093


IMBRUVICA® gives patients with 1L CLL/SLL an OPPORTUNITY TO LIVE LONGER and continue to experience the things they love1


95% estimated OS rate at 2 years with IMBRUVICA® (95% CI: 89, 97) vs 84% with chlorambucil (95% CI: 77, 90); HR=0.44 (95% CI: 0.21, 0.92)1

  • Overall survival was a secondary endpoint2
  • Median follow-up of 28.1 months1
  • 41% of chlorambucil-treated patients crossed over to IMBRUVICA® upon disease progression1

90% estimated PFS rate at 18 months with IMBRUVICA® vs 52% with chlorambucil HR=0.16 (95% CI: 0.09, 0.28; P<0.0001)1,2

  • Progression-free survival was the primary endpoint2
  • Median follow-up of 18.4 months2
  • Median PFS with IMBRUVICA® was not estimable vs 18.9 months (95% CI: 14.1, 22.0) with chlorambucil1

In RESONATE™-2, a randomized, multicenter, open-label, phase 3 trial of 269 patients ≥65 years with 1L CLL/SLL (patients with del17p were excluded).1,2

View I vs Clb in RESONATE™-2
BobCLL Patient

IMBRUVICA® has made me realize there’s hope.”

Long-term data from RESONATE™-2

The only BTKi with up to 8 years of follow-up data in 1L CLL/SLL.3

Explore the Data
Imbruvica® by your side patient support

IMBRUVICA® By Your Side patient support

By Your Side complements the prescribed treatment plan for all your IMBRUVICA® patients, ​providing education and resources to help them start and stay on track with treatment.

Learn More


1L=first-line, BTKi=Bruton’s tyrosine kinase inhibitor, CI=confidence interval, Clb=chlorambucil, CLL=chronic lymphocytic leukemia, HR=hazard ratio, I=IMBRUVICA®, OS=overall survival, PFS=progression-free survival, SLL=small lymphocytic lymphoma.


1IMBRUVICA® (ibrutinib) Prescribing Information. 2Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437. 3Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440-3450.